PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Finerenone→

Finerenone PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1050477-31-0
Molecular formula
C21H22N4O3
Molecular weight
378.4 g/mol
Drug class
Non-steroidal mineralocorticoid receptor antagonistcardiorenal protective agent
Mechanism of action
Selectively antagonises mineralocorticoid receptors, blocking aldosterone- and cortisol-mediated pro-inflammatory and profibrotic signalling in the kidney and cardiovascular system.
Indications / reported uses
  • Reduction of risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction and hospitalisation for heart failure in adults with chronic kidney disease associated with type 2 diabetes
  • Reduction of risk of cardiovascular death, heart failure hospitalisation and urgent heart failure visits in adults with heart failure and left ventricular ejection fraction at least 40% under the 2026 US label; check renal and potassium eligibility criteria

Sources: US DailyMed — KERENDIA (finerenone), label updated 2026 · NLM MeSH — Finerenone · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Finerenone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Finerenone Permitted Daily Exposure (PDE) report (the Finerenone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Finerenone Occupational Exposure Limit (OEL) report (the Finerenone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.